Status:
COMPLETED
Safety and Tolerability of BVS857 in Subjects With Insulin Resistance
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Insulin Resistance
Eligibility:
All Genders
18-64 years
Phase:
PHASE1
Brief Summary
The study will assess the safety, tolerability, drug label and effect in subjects with and without insulin resistance.
Eligibility Criteria
Inclusion
- Healthy male and female subjects with insulin resistance
- Subjects with controlled hypertension and hyperlipidemia
Exclusion
- Smokers
- History of drug or alcohol use
- Autonomic dysfunction
- Significant illness or cardiovascular disease
- Immunodeficiency disease
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
March 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT01435330
Start Date
March 1 2011
End Date
March 1 2012
Last Update
April 24 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Chula Vista, California, United States, 91910
2
Novartis Investigative Site
Tacoma, Washington, United States, 98418